Results 261 to 270 of about 172,684 (356)

Mechanisms of Resistance to Cancer Immunotherapy: A Host–Tumor Interaction Perspective; A Review Article

Cancer Nexus, EarlyView.
Mechanisms of resistance to cancer immunotherapy from a host–tumor interaction perspective. The central tumor cell is protected by multiple resistance mechanisms, including genetic mutations, epigenetic modifications, and metabolic alterations. The immunosuppressive tumor microenvironment features myeloid‐derived suppressor cells (MDSCs), regulatory T ...
Mohammed Elmujtba Adam Essa, Hamid Noori, Abdelkareem A. Ahmed   +2 more
wiley   +1 more source

Phase 1 Study of Maraviroc As Acute Graft-Versus-Host Disease Prophylaxis in Pediatrics

, 2016
Pooja Khandelwal, Tsuyoshi Fukuda, Ashley Teusink, Rebecca Marsh, Jack Bleesing, Alexander A. Vinks, Kana Mizuno, Angela D. M. Kashuba, Stella M. Davies   +8 more
openalex   +1 more source

Development of a humanized mouse model of graft-versus-host disease to assess human regulatory T cell function. [PDF]

Front Immunol
Beguin C, Kwan O, Ehx G, Humblet-Baron S, Köse MC, Dubois S, Canti L, Courtois J, Daulne C, Caers J, Beguin Y, Ritacco C, Baron F.   +12 more
europepmc   +1 more source

Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft‐Versus‐Host Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Axatilimab, a monoclonal antibody targeting colony‐stimulating factor 1 (CSF‐1) receptor, is approved in the US for the treatment of chronic graft‐versus‐host disease (cGVHD) after failure of ≥2 lines of systemic therapy. In this study, the effects of antidrug antibody (ADA) status on the pharmacokinetics, pharmacodynamics, efficacy, and safety of ...
Yan‐ou Yang, Xing Liu, Breann Barker, Xuecheng Zhang, Peter Ordentlich   +4 more
wiley   +1 more source

Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with Defibrotide. [PDF]

J Exp Pharmacol
Rimondi E, Melloni E, Secchiero P, Braidotti S, Maximova N, Marcuzzi A.   +5 more
europepmc   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Oral Manifestations of Graft Versus Host Disease – Clinical Presentations After Allogeneic Hematopoietic Cell Transplantation

Abdulhameed Alsarraf, Hessa Almusallam, Farah Alsalem, Qutaibah Alfadalah   +3 more
openalex   +1 more source

Acute graft-versus-host-disease after liver transplantation: Two case reports and literature review. [PDF]

Medicine (Baltimore)
Lei Q, Hong X, Zheng H, Su L, Chen H, Deng F.   +5 more
europepmc   +1 more source

Identification of neural crest and melanoma cancer cell invasion and migration genes using high‐throughput screening and deep attention networks

Developmental Dynamics, EarlyView.
Abstract Background Cell migration and invasion are well‐coordinated in development and disease but remain poorly understood. We previously showed that the neural crest (NC) cell migratory wavefront shares a 45‐gene panel with other cell invasion phenomena.
J. C. Kasemeier‐Kulesa, S. Martina Perez, R. E. Baker, P. M. Kulesa   +3 more
wiley   +1 more source

Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation

, 2019
Jingbo Yu, Jennifer Judy, Shreekant Parasuraman, Meenal Sinha, Daniel J. Weisdorf   +4 more
openalex   +1 more source